Latest Breaking News On - Thomas pieber - Page 3 : comparemela.com

JDRF, Lupus Research Alliance and National Multiple Sclerosis Society Join Forces to Decode Common Mechanisms of Autoimmune Diseases

NEW YORK, Feb. 24, 2021 /PRNewswire/ JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are

United statesStanford universitySan franciscoThomas pieberTeodora staevaChris cotsapasSanjoy duttaKevan heroldJulie zikhermanWilliam robinsonMark allegrettaAnsuman satpathyUniversity of californiaLupus research alliance board of directorsLupus research allianceNational multiple sclerosis society

Xeris Pharmaceuticals, Inc : Xeris Pharmaceuticals erhält von der Europäischen Kommission die Zulassung für die Ogluo-Injektion (Glucagon) zur Behandlung von schwerer Hypoglykämie bei Erwachsenen, Jugendlichen und Kindern ab 2 Jahren mit Diabetes mellitus

Xeris Pharmaceuticals, Inc : Xeris Pharmaceuticals erhält von der Europäischen Kommission die Zulassung für die Ogluo-Injektion (Glucagon) zur Behandlung von schwerer Hypoglykämie bei Erwachsenen, Jugendlichen und Kindern ab 2 Jahren mit Diabetes mellitus
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Schleswig holsteinUnited statesThomas pieberInstagram linkedinAdministration of gvokeAdministration of glucagonUnion as wellAmerican diabetes associationExchange commissionUniversity in austro grazAdministration of ogluoCommission approvalNovo nordiskHasa portfolio of solutionsXeris basedFurther step

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Posted on 7691 Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein. As the EC decision was received after the end of the Brexit transition period, Xeris will complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) is expected.

United statesUnited kingdomGreat britainThomas pieberAllison weyGvoke hypopenNovo nordisk glucagenPaulr edickXeris pharmaceuticalsDivision of endocrinologyAmerican diabetes associationEuropean unionPyramid laboratories incCommittee for medicinal products human useXeris pharmaceuticals incDepartment of internal medicine

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesThomas pieberAllison weyGvoke hypopenNovo nordisk glucagenPaulr edickDepartment of internal medicineXeris pharmaceuticals incXeris pharmaceuticalsEuropean commissionDivision of endocrinologyAmerican diabetes associationExchange commissionUniversity of grazCorporate communicationsEuropean medicines agency